Charles River Laboratories

Charles River and Metabolon partner on cancer research

Friday, April 6, 2012 10:54 AM

Charles River Discovery Services is partnering with Metabolon, a diagnostic products and services company based in Research Triangle Park, N.C., to enhance oncology research.

More... »


Charles River Labs to license EMD Millipore’s TrueSpike technology

Friday, March 2, 2012 06:00 AM

EMD Millipore, the life science division of Merck based in Billerica, Mass., will partner with Charles River Laboratories to exclusively license the TrueSpike technology, which reduces protein content of virus preparations and increases predictability of validation studies.

More... »


Charles River posts quarterly and full-year 2011 results

Friday, February 17, 2012 01:40 PM

Charles River Laboratories has reported financial results for the fourth quarter and for full-year 2011.

More... »

Charles River Labs launches online community Eureka

Thursday, January 26, 2012 10:59 AM

Charles River Laboratories has launched Eureka, an online community for scientists “to explore, connect and share big ideas.” The site profiles scientific professionals at Charles River Labs and welcomes industry experts to share their research and opinions on industry topics and questions.

More... »

Charles River provides financial guidance for 2012

Thursday, December 15, 2011 02:59 PM

Charles River Laboratories International has provided guidance for 2012 and updated guidance for 2011. James C. Foster, Chairman, president and chief executive officer, said, “We made significant progress in 2011 on our four key initiatives, which include operating margin expansion, improved free cash flow, disciplined investment in existing growth businesses, and returning value to shareholders. In 2012, we will maintain our focus on these initiatives and on stimulating sales growth.”

More... »

Survey: 80% of big pharma companies restructuring to strategically outsource more trials to CROs

Monday, October 31, 2011 08:00 AM

According to a recent survey from William Blair, about 80% of big pharma companies either are in the process of restructuring or have already completed restructuring plans to strategically outsource more of their trials to CROs.

More... »

Protagen, Charles River form marketing alliance

Friday, October 28, 2011 10:39 AM

Protagen and Charles River Laboratories International have formed a strategic marketing & sales alliance.

More... »

ShangPharma acquires Charles River’s Shanghai facility

Monday, October 24, 2011 10:49 AM

ShangPharma, a China-based pharmaceutical and biotechnology research and development outsourcing company, has acquired the assets in Charles River Laboratories International’s Shanghai research facility.

More... »

PPD shares rise on takeover rumors

Monday, July 18, 2011 01:51 PM

Shares of CRO Pharmaceutical Product Development (PPD) rose 16% to levels not touched in more than two-and-a-half years on Monday, a day after a Wall Street Journal report said the company was looking to sell itself, reported Reuters.

More... »

ADDF, Charles River collaborate in research award program

Wednesday, July 13, 2011 10:27 AM

The Alzheimer's Drug Discovery Foundation (ADDF) is collaborating with Charles River Laboratories International, a provider of early-stage drug development products and services, to create a new research award program entitled Use of Aged Rats as a Relevant Pre-clinical Model for the Development of Therapies for Cognitive Aging and Alzheimer's Disease.  The program is made possible through a donation from Charles River's Discovery Services business and funds from the ADDF.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs